Literature DB >> 19342675

Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis.

Julia-Stefanie Frick1, Christopher F MacManus, Melanie Scully, Louise E Glover, Holger K Eltzschig, Sean P Colgan.   

Abstract

Inflammatory diseases influence tissue metabolism, significantly altering the profile of extracellular adenine nucleotides. A number of studies have suggested that adenosine (Ado) may function as an endogenously generated anti-inflammatory molecule. Given the central role of intestinal epithelial cells to the development of colitis, we hypothesized that specific Ado receptors would contribute to disease resolution in mucosal inflammation as modeled by dextran sodium sulfate (DSS) colitis. Initial profiling studies revealed that murine intestinal epithelial cells express predominantly the Ado A2B receptor (AA2BR) and to a lesser extent AA2AR. Guided by these results, we examined the contribution of AA2BR to colitis. Initial studies indicated that the severity of colitis was increased in Aa2br(-/-) mice relative to Aa2br(+/+) controls, as reflected by increased weight loss, colonic shortening, and disease activity indices. Likewise, enteral administration of the selective AA2BR inhibitor PSB1115 to Aa2br(+/+) mice resulted in a similar increase in severity of DSS colitis. Cytokine profiling of colonic tissue revealed specific deficiencies in IL-10 in Aa2br(-/-) mice relative to controls. Extensions of these findings in cultured human intestinal epithelial cells revealed that stable Ado analogs induce IL-10 mRNA and protein and that such increases can be blocked with PSB1115. Taken together, these studies indicate a central regulatory role for AA2BR-modulated IL-10 in the acute inflammatory phase of DSS colitis, thereby implicating AA2BR as an endogenously protective molecule expressed on intestinal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342675      PMCID: PMC2831100          DOI: 10.4049/jimmunol.0801324

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling.

Authors:  S P Colgan; R M Hershberg; G T Furuta; R S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Animal models of mucosal inflammation and their relation to human inflammatory bowel disease.

Authors:  R S Blumberg; L J Saubermann; W Strober
Journal:  Curr Opin Immunol       Date:  1999-12       Impact factor: 7.486

3.  Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells.

Authors:  C Platzer; E Fritsch; T Elsner; M H Lehmann; H D Volk; S Prösch
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

4.  Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability.

Authors:  Katrina M Comerford; Donald W Lawrence; Kristin Synnestvedt; Boaz P Levi; Sean P Colgan
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

Review 5.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Authors:  J Linden
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

6.  Role of VASP in reestablishment of epithelial tight junction assembly after Ca2+ switch.

Authors:  Donald W Lawrence; Katrina M Comerford; Sean P Colgan
Journal:  Am J Physiol Cell Physiol       Date:  2002-06       Impact factor: 4.249

7.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia.

Authors:  Kristin Synnestvedt; Glenn T Furuta; Katrina M Comerford; Nancy Louis; Jorn Karhausen; Holger K Eltzschig; Karl R Hansen; Linda F Thompson; Sean P Colgan
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

8.  Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.

Authors:  G Hartmann; C Bidlingmaier; B Siegmund; S Albrich; J Schulze; K Tschoep; A Eigler; H A Lehr; S Endres
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

9.  A2B adenosine receptor gene deletion attenuates murine colitis.

Authors:  Vasantha L Kolachala; Matam Vijay-Kumar; Guillaiume Dalmasso; Dan Yang; Joel Linden; Lixin Wang; Andrew Gewirtz; Katya Ravid; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

Review 10.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  90 in total

Review 1.  Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery.

Authors:  Sean P Colgan; Holger K Eltzschig
Journal:  Annu Rev Physiol       Date:  2011-11-19       Impact factor: 19.318

2.  Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury.

Authors:  Ulrich Schingnitz; Katherine Hartmann; Christopher F Macmanus; Tobias Eckle; Stephanie Zug; Sean P Colgan; Holger K Eltzschig
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

Review 3.  Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia.

Authors:  Almut Grenz; Dirk Homann; Holger K Eltzschig
Journal:  Antioxid Redox Signal       Date:  2011-04-11       Impact factor: 8.401

4.  IFN-γ attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1β.

Authors:  Louise E Glover; Karina Irizarry; Melanie Scully; Eric L Campbell; Brittelle E Bowers; Carol M Aherne; Douglas J Kominsky; Christopher F MacManus; Sean P Colgan
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

5.  A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis.

Authors:  Sarah A Ingersoll; Hamed Laroui; Vasantha L Kolachala; Lixin Wang; Pallavi Garg; Timothy L Denning; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Dig Liver Dis       Date:  2012-06-19       Impact factor: 4.088

Review 6.  Adenosine receptors and caffeine in retinopathy of prematurity.

Authors:  Jiang-Fan Chen; Shuya Zhang; Rong Zhou; Zhenlang Lin; Xiaohong Cai; Jing Lin; Yuqing Huo; Xiaoling Liu
Journal:  Mol Aspects Med       Date:  2017-01-11

Review 7.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

8.  Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats.

Authors:  L Antonioli; M Fornai; O Awwad; G Giustarini; C Pellegrini; M Tuccori; V Caputi; M Qesari; I Castagliuolo; P Brun; M C Giron; C Scarpignato; C Blandizzi; R Colucci
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  Elevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension.

Authors:  Weiru Zhang; Yujin Zhang; Wei Wang; Yingbo Dai; Chen Ning; Renna Luo; Kaiqi Sun; Louise Glover; Almut Grenz; Hong Sun; Lijian Tao; Wenzheng Zhang; Sean P Colgan; Michael R Blackburn; Holger K Eltzschig; Rodney E Kellems; Yang Xia
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

10.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.